Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pernix Reinvention Comes Down To Execution

This article was originally published in The Pink Sheet Daily

Executive Summary

Pernix has a new management team and a budding portfolio of CNS drugs, gained via M&A. Now the company needs to prove it can grow brands that compete in highly genericized markets and drive sustainable growth.

You may also be interested in...



High Deal Valuations & Volumes Will Persist, Industry Dealmakers Predict

Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.

Latecomer Libtayo Wins Coveted First-Line NSCLC Monotherapy Indication

Sanofi/Regeneron's PD-1 inhibitor Libtayo joins Keytruda and Tecentriq as the only PD-1/L1s approved by the US FDA as monotherapy for first-line non-small cell lung cancer.

Regeneron's Evkeeza Approved For Ultra-Rare Genetic High Cholesterol – And Priced To Match

Evkeeza is the first ANGPTL3 approved by the FDA; Regeneron scientists discovered the angiopoetin gene family.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel